Brought to you by 
Altheos gets rights to Asahi Kasei's glaucoma compounds
03 May 2010
Executive Summary
Altheos Inc. (ophthalmic therapeutics) has received exclusive global rights, except in Japan and Korea, to Asahi Kasei Pharma Corp.'s preclinical AK138 series of selective Rho kinase inhibitors for the topical treatment of glaucoma.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Altheos gets rights to Asahi Kasei's glaucoma compounds
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice